XOLAIR (omalizumab) Patient Assistance Program
Don’t let the high cost of brand specialty allergy/asthma biologics stand between you and
the treatment you need. We help eligible patients access Xolair (omalizumab) for as little
as $69.95 per month through the manufacturer's Patient Assistance Program.
- Clear & Transparent Pricing
- Paperwork & Doctor-Coordination
- Comprehensive Support: From Application to Entire Journey
- Annual Re-certification And Refills Management
- Medicare Part D Patients Accepted
HIPAA Compliant
BBB Accredited
Secure Website
Key Takeaways:
- Xolair (omalizumab) is FDA-approved for moderate-to-severe persistent allergic asthma in patients 6 and older with elevated IgE and a positive skin-test or in vitro reactivity to a perennial aeroallergen, chronic spontaneous urticaria (CSU) in patients 12 and older inadequately controlled by H1 antihistamines, chronic rhinosinusitis with nasal polyps, and IgE-mediated food allergy (for reduction of allergic reactions including anaphylaxis after accidental exposure). It is given as a subcutaneous injection.
- Without assistance, the average retail price varies by weight and IgE level: typical doses cost approximately $2,000–$4,000+ per month at common dosing schedules, with annual costs commonly $25,000–$50,000+.
- Through AffordMyPrescriptions, qualifying patients can access Xolair for a flat $69.95 per month — our advocacy team manages the entire enrollment, refills, and renewal process.
- An interchangeable biosimilar to Xolair (Omlyclo) was FDA-approved in 2025 — substitution depends on your prescriber and pharmacy. Other anti-IgE-class therapies are not yet available.
What is Xolair Prescription Assistance Program?
The Xolair Prescription Assistance Program is a manufacturer-sponsored initiative that provides Xolair at little or no medication cost to qualifying patients based on income and insurance status. The program is designed for severe asthma, CSU, nasal polyp, and food-allergy patients who are uninsured or
underinsured, as well as Medicare Part D beneficiaries.
Navigating the program on your own means dealing with eligibility verification, allergy/pulmonology coordination, IgE testing documentation, prior-authorization documentation, specialty pharmacy logistics, and renewal deadlines.
AffordMyPrescriptions eliminates that burden. For a flat $69.95 per month, our Patient Advocates handle every step of your enrollment, from initial application through ongoing refill coordination and annual re-certification — so you focus on your health, not paperwork.
Pharmacy Price Comparison
- Without assistance, Xolair costs vary widely by weight and IgE level — commonly $2,000–$4,000+ per month. A biosimilar (Omlyclo) is now available at lower cost. A Patient Assistance Program is the meaningful path for brand pricing — if you qualify:
| Pharmacy(With Coupon) | PrIce (30-Day)* | You Save W/ Us |
|---|---|---|
| Per dose 75 mg (brand) | ~$1,200.00 | Save ~$1,130/dose |
| Per dose 150 mg (brand) | ~$2,400.00 | Save ~$2,330/dose |
| Per dose 300 mg (brand) | ~$4,800.00 | Save ~$4,730/dose |
| Biosimilar (Omlyclo) | ~30–40% lower | Significant savings |
| Annual cost (typical) | ~$30,000+ | Save ~$29,000+/yr |
*Retail prices are estimates based on public data and vary by pharmacy. Coupon prices from GoodRx and SingleCare as of April 2026. Afford My Prescriptions Advocacy Service bypasses retail pricing by using drug manufacturer programs to secure your medication for you—independent of dosage or retail price.
Our Pricing:
$69.95 Per month
1 Medications
$79.95 Per Month
2 Medications
$89.95 Per Month
3 Medications
$99.95 Per Month
4+ Medications
Why choose us For Your Xolair Prescription Program?
The Patient Assistance Program is free to apply for and provides Xolair at no medication cost if approved. But the process involves detailed applications, prescriber coordination, IgE testing documentation, prior-authorization documentation, specialty pharmacy logistics, and ongoing renewal management. Our $69.95/month service covers full advocacy. With Omlyclo (Xolair biosimilar) now available at lower cost, we'll guide you to the most cost-effective path.
Enroll
Complete a simple eligibility form so our team can determine if you may qualify for medication assistance programs.
We Advocate
Our specialists help gather documentation, complete applications, and coordinate with program providers.
Receive Medication
Once approved, you may receive your medication through the assistance program while we help manage ongoing paperwork and renewals.
Discount Coupons vs. Patient Assistance Programs
Many patients try discount cards first. Here’s why the Patient Assistance Program through AffordMyPrescriptions is the better long-term solution for Xolair:
Limitations of Coupons
Prices fluctuate — savings aren’t guaranteed month-to-month
Copay accumulators may prevent savings from counting toward your deductible
Coupon cards expire and require constant renewal
Still $13,000–$15,000 per month even
with the best discountCannot be used with Medicare, Medicaid, or government insurance
Advantages of PAP Through Us
Fixed $69.95/month — never changes regardless of retail price
- No expiration — continuous access as long as you qualify
Medication supplied directly through the assistance program
We manage all paperwork, refills, and annual renewals
Medicare Part D patients accepted
DO YOU QUALIFY?
Eligibility is generally determined by annual household income and insurance status. Most programs follow guidelines that include limits of up to $40,000 for individuals, $60,000 for couples, and $100,000 for larger families. Because requirements vary by program and household, we encourage you to contact AffordMyPrescriptions directly so we can review your specific situation and determine if you qualify for Xolair assistance.
- You are a U.S. citizen or legal resident
- You Have A Valid Vidaza Prescription From A Licensed U.S. Healthcare Provider
- You Are Uninsured, Underinsured, Or A Medicare Part D Beneficiary
- You Have Recently Experienced A Change In Financial Circumstances That Affects Your Ability To Pay
Understanding Xolair:
Xolair (omalizumab) is a biologic medicine in the anti-IgE class used to treat several IgE-mediated allergic conditions — moderate-to-severe persistent allergic asthma, chronic spontaneous urticaria (CSU), chronic rhinosinusitis with nasal polyps, and IgE-mediated food allergy. It is given as a subcutaneous injection every 2–4 weeks based on weight and IgE level.
How It Works:
Allergic asthma, CSU, nasal polyps, and food allergies are all driven in part by immunoglobulin E (IgE) — an antibody class that recognizes allergens and triggers allergic responses by activating mast cells and basophils. When IgE binds its high-affinity receptor (FcεRI) on these immune cells and then encounters an allergen, the cells release histamine, leukotrienes, and other inflammatory mediators that produce allergic symptoms.
Xolair is a monoclonal antibody that binds to free IgE and prevents it from connecting to FcεRI on mast cells and basophils. By neutralizing free IgE, Xolair reduces the activation of these cells in response to allergens — producing fewer asthma exacerbations, less hive activity in CSU, smaller nasal polyps,
and reduced reactivity to food allergens. Xolair was the first anti-IgE biologic approved (2003) and remains the foundational anti-IgE therapy.
Form and Use:
Xolair is given as a subcutaneous injection every 2 or 4 weeks. The dose is determined by weight and pretreatment serum total IgE level (calculated from a manufacturer dosing chart). A prefilled syringe and a prefilled autoinjector are available for self-administration after training; some patients receive their injections in a healthcare setting due to anaphylaxis risk during the first several doses.
Generic Availability:
An FDA-approved interchangeable biosimilar to Xolair — Omlyclo (omalizumab-igec) — was approved in 2025 and provides a lower-cost alternative for many patients. Other severe asthma biologics target different mechanisms (anti-IL-5, anti-IL-4Rα, anti-TSLP) and are options for patients without an IgE-dominant phenotype. Whether Xolair, Omlyclo, or a different biologic is a better fit depends on the indication, biomarker profile, prior treatments, and tolerability.
Warnings:
Xolair carries a boxed warning for anaphylaxis. Anaphylaxis has occurred during and after Xolair administration — patients should be observed for an appropriate period after injection (especially during early doses), and patients/caregivers should be instructed on the signs of anaphylaxis. Patients receiving Xolair are typically prescribed an epinephrine autoinjector. Other warnings include malignancies (small numerical imbalance in some studies), eosinophilic conditions (vasculitis), serum
sickness, and parasitic (helminth) infections.
FAQ (Frequently Asked Questions)
How Much Does Xolair Cost Without Insurance?+
Xolair costs vary widely based on the dose (which is determined by weight and IgE level). Typical costs run $1,200–$4,800 per dose, with monthly totals of $2,000–$4,000+ depending on dose and frequency. Annual costs commonly reach $25,000–$50,000+. The Omlyclo biosimilar is significantly cheaper. Through AffordMyPrescriptions, qualifying patients receive Xolair at no medication cost — our $69.95 monthly fee covers full advocacy and program management.
Is The Omlyclo Biosimilar The Same Medicine?+
Yes. Omlyclo (omalizumab-igec) is FDA-approved as an interchangeable biosimilar to Xolair. It contains the same active ingredient and produces the same clinical results. Whether your prescription is filled as brand Xolair or as Omlyclo depends on your prescriber's decision, the specialty pharmacy, and your insurance — for many patients, Omlyclo at lower cost is the right path.
How Is Xolair Given?+
Xolair is given as a subcutaneous injection every 2 or 4 weeks. The dose is determined by weight and pretreatment serum total IgE level (calculated from a manufacturer dosing chart). A prefilled autoinjector or syringe is available. Initial doses are typically given in a healthcare setting because of anaphylaxis risk; many patients can transition to home self-administration after several supervised doses.
Why Is Anaphylaxis Risk Highlighted?+
Xolair carries a boxed warning for anaphylaxis, which has occurred during and after administration. Most reactions occur within the first 2 hours after injection, but delayed
reactions are possible. Patients are observed for a defined period after early doses (typically 2 hours for the first 3 doses, then 30 minutes thereafter). Patients and caregivers are taught to recognize anaphylaxis signs (swelling, difficulty breathing, low blood pressure) and are typically prescribed an epinephrine autoinjector.
What If My Application Is Denied?+
If your initial application is denied, we explore alternatives — switching to the Omlyclo biosimilar, the manufacturer’s copay savings program if you have commercial insurance, independent foundations such as the Asthma and Allergy Foundation of America, FARE (Food Allergy Research & Education), American Academy of Dermatology, PAN Foundation, or HealthWell Foundation, or asking your prescriber whether a different severe asthma biologic (Nucala, Fasenra, Dupixent, Tezspire) would be appropriate. If we cannot find a path, you will not be charged our service fee.
Take Control of Your Medication Costs
If you are struggling with the high cost of Xolair, our team may be able to help you access assistance programs — or guide you to the cheaper Omlyclo biosimilar if it is the better fit. Check your eligibility today.
Submit Enrollment Form
Start free by filling out a simple online form.
Receive Welcome Call
Our specialist will contact you for a quick welcome call.
We Manage The Process
Our team handles everything, so you can focus on your health.